{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:20:11Z","timestamp":1769811611186,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":2100,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1111\/j.1469-0691.2009.02740.x","type":"journal-article","created":{"date-parts":[[2009,3,20]],"date-time":"2009-03-20T13:46:57Z","timestamp":1237556817000},"page":"218-223","source":"Crossref","is-referenced-by-count":48,"title":["Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens"],"prefix":"10.1016","volume":"15","author":[{"given":"G.","family":"Cornaglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.M.","family":"Rossolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 6","key":"10.1111\/j.1469-0691.2009.02740.x_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2008.02126.x","article-title":"Antimicrobial resistance in Europe and its potential impact on empirical therapy","volume":"14","author":"Rossolini","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"3 suppl 1","key":"10.1111\/j.1469-0691.2009.02740.x_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3810\/pgm.2008.09.suppl52.278","article-title":"Antimicrobial susceptibility patterns in the United States and globally: findings of the TRUST and GLOBAL surveillance studies","volume":"120","author":"Jenkins","year":"2008","journal-title":"Postgrad Med"},{"issue":"6 suppl 1","key":"10.1111\/j.1469-0691.2009.02740.x_bib3","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.amjmed.2006.03.012","article-title":"Antimicrobial resistance in gram-positive bacteria","volume":"119","author":"Rice","year":"2006","journal-title":"Am J Med"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2009.02740.x_bib4","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib5","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.00620-06","article-title":"Bactericidal activity and resistance development profiling of dalbavancin","volume":"51","author":"Goldstein","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2009.02740.x_bib6","doi-asserted-by":"crossref","first-page":"ii21","DOI":"10.1093\/jac\/dki007","article-title":"In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide","volume":"55","author":"Lopez","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2009.02740.x_bib7","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dki008","article-title":"Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide","volume":"55","author":"Dorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jac\/dkl281","article-title":"Effect of dalbavancin on the normal intestinal microflora","volume":"58","author":"Nord","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib12","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.43.8.1875","article-title":"Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci","volume":"43","author":"Arthur","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib14","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/AAC.47.5.1700-1706.2003","article-title":"Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection","volume":"47","author":"Boylan","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib15","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.42.10.2564","article-title":"Comparison of inhibitory and bactericidal activities and post-antibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium","volume":"42","author":"Baltch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional Iipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillm-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Leuthner","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dkn124","article-title":"In vitro activity of telavancin against recent gram-positive clinical isolates: results of the 2004\u201305 Prospective European Surveillance Initiative","volume":"62","author":"Draghi","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib19","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.48.8.3043-3050.2004","article-title":"Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria","volume":"48","author":"Hegde","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/13543784.16.3.347","article-title":"Telavancin: a novel lipoglycopeptide for serious gram-positive infections","volume":"16","author":"Laohavaleeson","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib21","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1586\/14787210.6.6.917","article-title":"Vancomycin resistance, are there glycopeptides coming?","volume":"6","author":"Linden","year":"2008","journal-title":"Exp Rev Anti Infect Ther"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.coph.2006.06.002","article-title":"Anti-MRSA beta-lactams in development","volume":"6","author":"Page","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/13543784.16.4.419","article-title":"Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy","volume":"16","author":"Bush","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.45.3.825-836.2001","article-title":"In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci","volume":"45","author":"Hebeisen","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib25","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1128\/AAC.49.10.4210-4219.2005","article-title":"Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin","volume":"49","author":"Bogdanovich","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib26","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1128\/AAC.49.5.1932-1942.2005","article-title":"Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin","volume":"49","author":"Kosowska","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib29","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.bmcl.2003.07.023","article-title":"Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria","volume":"13","author":"Schneider","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib30","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/13543784.16.9.1441","article-title":"Iclaprim","volume":"16","author":"Kohlhoff","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib31","first-page":"210","article-title":"Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections","volume":"9","author":"Peppard","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/526772","article-title":"Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic","volume":"46","author":"Billeter","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib33","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1128\/AAC.01641-07","article-title":"Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States","volume":"52","author":"Draghi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2009.02740.x_bib13","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/AAC.00360-08","article-title":"Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax","volume":"52","author":"Heine","year":"2008","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1462139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1462139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T20:36:25Z","timestamp":1558211785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X1462139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1198743X1462139X"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2009.02740.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}